Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide

• Status: Completed
• Trial end date: 2006-04-12
• Target enrollment: 0
• Participant gender: All

Summary

To determine the percentage of patients and number of cycles in which a packed red blood cell transfusion was administered due to anemia and in which antibiotics were administered due to neutropenic fever.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: Amgen
• Treatments: Darbepoetin alfa; Doxorubicin; Ifosfamide; Isophosphamide mustard; Liposomal doxorubicin

Criteria

Inclusion Criteria:

• Patients with sarcoma which is locally advanced, at high risk for relapsed or metastatic for whom treatment with AI is indicated

• Must be between 18-65 years of age

• Women of childbearing potential should use effective contraceptive measures

• Adequate hematologic, renal, and hepatic functions

• Karnofsky performance status above or equal to 80

Exclusion Criteria:

• Pregnant or lactating women.

• Patients with comorbid condition which renders patients at high risk of treatment complication

• Patients with metastatic disease to CNS

• Patients with significant cardiac abnormalities

• History of seizure disorder in the past 5 years

• Patient has received any packed red blood cell transfusion within 2 weeks before study entry

• Prior surgery or radiation therapy within 2 weeks of study entry

• History of prior chemotherapy for sarcomas

• Iron deficiency

• Hypersensitivity to E.coli derived products